247 results on '"Chunyou Wang"'
Search Results
2. Clinical-radiomics nomogram using contrast-enhanced CT to predict histological grade and survival in pancreatic ductal adenocarcinoma
- Author
-
Chunyuan Cen, Chunyou Wang, Siqi Wang, Kan Wen, Liying Liu, Xin Li, Linxia Wu, Mengting Huang, Ling Ma, Huan Liu, Heshui Wu, and Ping Han
- Subjects
pancreatic ductal adenocarcinoma ,x-ray computed tomography ,radiomics ,histological grade ,overall survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ObjectivesTumor grading is important for prognosis of pancreatic ductal adenocarcinoma (PDAC). In this study, we developed preoperative clinical-radiomics nomograms using features from contrast-enhanced CT (CECT), to discriminate high-grade and low-grade PDAC and predict overall survival (OS).MethodsIn this single-center, retrospective study conducted from February 2014 to April 2021, consecutive PDAC patients who underwent CECT and had pathologically identified grading were randomized to training (n=200) and test (n=84) cohorts for development of model to predict histological grade based on radiomics scores from CECT (HGrad). Another 42 patients were used as external validation cohort of HGrad. A nomogram (HGnom) was constructed using radiomics score, CA12-5 and smoking to predict histological grade. A second nomogram (Pnom) was constructed using radiomics score, CA12-5, TNM, adjuvant treatment, resection margin and microvascular invasion to predict OS in radical resection patients (217 of 284).ResultsAmong 326 patients, 122 were high-grade (120 poorly differentiated and 2 undifferentiated). The HGrad yielded AUCs of 0.75 (95% CI: 0.64, 0.85) and 0.76 (95% CI: 0.60, 0.91) in test and validation cohorts. The HGnom achieved AUCs of 0.77 (95% CI: 0.66, 0.87), and the predicted grades calibrated well with actual grades (P=.13). OS was different between the grades predicted by radiomics scores (P=.01). The integrated AUC of the Pnom for predicting OS was 0.80 (95% CI: 0.75, 0.88).ConclusionCompared with the HGrad using features from CECT, the HGnom demonstrated higher performance for predicting histological grade. The Pnom helped identify patients with high survival outcome in pancreatic ductal adenocarcinoma.
- Published
- 2023
- Full Text
- View/download PDF
3. Circular RNA circLOC101928570 suppresses systemic lupus erythematosus progression by targeting the miR-150-5p/c-myb axis
- Author
-
Xingwang Zhao, Rui Dong, Zhongwei Tang, Juan Wang, Chunyou Wang, Zhiqiang Song, Bing Ni, Longlong Zhang, Xiaochong He, and Yi You
- Subjects
Systemic lupus erythematosus ,circLOC101928570 ,miR-150-5p ,c-myb ,Biomarker ,Medicine - Abstract
Abstract Background Accumulating evidence supports the implication of circular RNAs (circRNAs) in systemic lupus erythematosus (SLE). However, little is known about the detailed mechanisms and roles of circRNAs in the pathogenesis of SLE. Methods Quantitative real-time PCR was used to determine the levels of circLOC101928570 and miR-150-5p in peripheral blood mononuclear cells of SLE. Overexpression and knockdown experiments were conducted to assess the effects of circLOC101928570. Fluorescence in situ hybridization, RNA immunoprecipitation, luciferase reporter assays, Western blot, flow cytometry analysis and enzyme-linked immunosorbent assay were used to investigate the molecular mechanisms underlying the function of circLOC101928570. Results The results showed that the level of circLOC101928570 was significantly downregulated in SLE and correlated with the systemic lupus erythematosus disease activity index. Functionally, circLOC101928570 acted as a miR-150-5p sponge to relieve the repressive effect on its target c-myb, which modulates the activation of immune inflammatory responses. CircLOC101928570 knockdown enhanced apoptosis. Moreover, circLOC101928570 promoted the transcriptional level of IL2RA by directly regulating the miR-150-5p/c-myb axis. Conclusion Overall, our findings demonstrated that circLOC101928570 played a critical role in SLE. The downregulation of circLOC101928570 suppressed SLE progression through the miR-150-5p/c-myb/IL2RA axis. Our findings identified that circLOC101928570 serves as a potential biomarker for the diagnosis and therapy of SLE.
- Published
- 2022
- Full Text
- View/download PDF
4. Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome
- Author
-
Chunyuan Cen, Liying Liu, Xin Li, Ailan Wu, Huan Liu, Xinrong Wang, Heshui Wu, Chunyou Wang, Ping Han, and Siqi Wang
- Subjects
pancreatic ductal adenocarcinoma ,computed tomography ,radiomics ,nomogram ,cancer staging ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ObjectivesTo construct a nomogram model that combines clinical characteristics and radiomics signatures to preoperatively discriminate pancreatic ductal adenocarcinoma (PDAC) in stage I-II and III-IV and predict overall survival.MethodsA total of 135 patients with histopathologically confirmed PDAC who underwent contrast-enhanced CT were included. A total of 384 radiomics features were extracted from arterial phase (AP) or portal venous phase (PVP) images. Four steps were used for feature selection, and multivariable logistic regression analysis were used to build radiomics signatures and combined nomogram model. Performance of the proposed model was assessed by using receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA). Kaplan-Meier analysis was applied to analyze overall survival in the stage I-II and III-IV PDAC groups.ResultsThe AP+PVP radiomics signature showed the best performance among the three radiomics signatures [training cohort: area under the curve (AUC) = 0.919; validation cohort: AUC = 0.831]. The combined nomogram model integrating AP+PVP radiomics signature with clinical characteristics (tumor location, carcinoembryonic antigen level, and tumor maximum diameter) demonstrated the best discrimination performance (training cohort: AUC = 0.940; validation cohort: AUC = 0.912). Calibration curves and DCA verified the clinical usefulness of the combined nomogram model. Kaplan-Meier analysis showed that overall survival of patients in the predicted stage I-II PDAC group was longer than patients in stage III-IV PDAC group (p
- Published
- 2021
- Full Text
- View/download PDF
5. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer
- Author
-
Hengqiang Zhao, Shihong Wu, Hehe Li, Qingke Duan, Zhengle Zhang, Qiang Shen, Chunyou Wang, and Tao Yin
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM). Glucose metabolism has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells. However, few studies have focused on the effects of GEM on cancer cell metabolism, stemness of tumor cells, and molecular mechanisms that critically influence PanCa treatment. We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidation and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells. Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM’s cytotoxicity. GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift. GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness. In addition, GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway. This effect was validated by introducing exogenous hydrogen peroxide (H2O2). Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment. Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients. Keywords: ROS, KRAS, AMPK, aerobic glycolysis, cancer stem cells, pancreatic cancer, chemotherapy
- Published
- 2019
- Full Text
- View/download PDF
6. The current surgical treatment of pancreatic neuroendocrine neoplasms in China: a national wide cross-sectional study
- Author
-
Wenming Wu, MD, Gang Jin, MD, Haimin Li, MD, Yi Miao, MD, Chunyou Wang, MD, Tingbo Liang, MD, Jinrui Ou, MD, Yongfu Zhao, MD, Chunhui Yuan, MD, Yixiong Li, MD, Wenhui Lou, MD, Zheng Wu, MD, Renyi Qin, MD, Huaizhi Wang, MD, Jihui Hao, MD, Xianjun Yu, MD, Heguang Huang, MD, Guang Tan, MD, Xubao Liu, MD, Kesen Xu, MD, Lei Wang, MD, Yinmo Yang, MD, Chunyi Hao, MD, Weilin Wang, MD, Kejian Guo, MD, Junmin Wei, MD, Yifan Wang, MD, Chenghong Peng, MD, Xuefeng Wang, MD, Shouwang Cai, MD, Jianxin Jiang, MD, Xinmin Wu, MD, Xiao Yu, MD, Fei Li, MD, Yupei Zhao, MD, and Pancreatic Surgery Study Group of Chinese Society of Surgery of Chinese Medical Association
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Objective:. The aim of this study is to investigate the current status of the diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms (pNENs) undergoing surgery in China. Methods:. This is a multicenter cross-sectional study performed in China. Data from patients with pNENs undergoing surgery at 33 high-volume medical centers, where the number of pancreatectomies exceeds 20 cases per year, were collected and analyzed between March 1, 2016 and February 28, 2017. Results:. In total, 392 patients with pNENs were enrolled. The male to female ratio was 1.4. The majority of patients were aged between 40 and 70 years. 65.6% of the patients had non-functional tumors. Among those with functional tumors, the percentages of insulinomas, gastrinomas, glucagonomas, and vasoactive intestinal peptide-secreting tumors were 94.8%, 1.5%, 2.2%, and 1.5%, respectively. Multidisciplinary team (MDT) discussion was conducted for 39.0% of the patients. Minimally invasive surgery was performed on 31.1% of the 392 patients. The incidence of grade B/C pancreatic fistula formation was 4.4%. A total of 89.0% of the surgeries achieved R0 resection, and 41.6% of the tumors were well differentiated. Lymph node metastasis was present in 8.9% of the patients. The percentages of patients with grades G1, G2, and G3 disease were 49.2%, 45.7%, and 5.1%, respectively. Conclusion:. This multicenter cross-sectional study systematically presents the current status of the diagnosis and treatment of patients with pNENs undergoing surgery in China. MDT consultation for pNENs has not been widely implemented in China. Although the incidence of surgical complications is relatively low, minimally invasive procedures should be further promoted. This study shows us how to improve the outcomes of these patients.
- Published
- 2019
- Full Text
- View/download PDF
7. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
- Author
-
Hehe Li, Zhengle Zhang, Chenggang Gao, Shihong Wu, Qingke Duan, Heshui Wu, Chunyou Wang, Qiang Shen, and Tao Yin
- Subjects
Pancreatic cancer ,Gemcitabine ,Valproic acid ,Combined chemotherapy ,Bmi1 ,Biotechnology ,TP248.13-248.65 ,Biology (General) ,QH301-705.5 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Gemcitabine is the standard first-line chemotherapy regimen for pancreatic cancer. However, its therapeutic value is substantially limited in pancreatic cancer patients due to occurrence of resistance towards gemcitabine. A strategy of combined chemo-regimens is widely employed in clinical settings in attempt to reduce the chance of developing therapeutic resistance. Valproic acid (VPA) has been reported as a promising anticancer drug in various clinical trials and studies. However, the clinical value and potential dose–effect of VPA in combination with gemcitabine for pancreatic cancer treatment are under investigated. Results In this study, we determined the synergistic effect of VPA and gemcitabine and found that high-dose VPA significantly and dose-dependently enhanced the sensitivity of pancreatic cancer cells to gemcitabine. Intriguingly, low-dose VPA potentiated the migration and invasion of pancreatic cancer cells that already showed gemcitabine-induced motility. Moreover, low-dose VPA increased the reactive oxygen species (ROS) production, which activated AKT to further stimulate the activation of STAT3, Bmi1 expression and eventually promoted the migration and invasion of pancreatic cancer cells induced by gemcitabine. Whereas high-dose VPA stimulated excessive ROS accumulation that promoted p38 activation, which suppressed the activation of STAT3 and Bmi1. Conclusion Pancreatic cancer cells respond differentially towards low- or high-dose of VPA in combination with gemcitabine, and a low VPA further potentiate pancreatic cancer cell to migrate and invade. Our results suggest that STAT3/Bmi1 signaling cascade, which is regulated by ROS-dependent, AKT- or p38-modulated pathways, primarily mediated the sensitivity and motility of pancreatic cancer cells towards combined gemcitabine and VPA regimen. These findings suggest a highly clinically relevant new mechanism of developing resistance against combined chemo-regimens, warranting further mechanistic and translational exploration for VPA in combination with gemcitabine and other chemotherapies.
- Published
- 2019
- Full Text
- View/download PDF
8. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway
- Author
-
Qingke Duan, Hehe Li, Chenggang Gao, Hengqiang Zhao, Shihong Wu, Heshui Wu, Chunyou Wang, Qiang Shen, and Tao Yin
- Subjects
Pancreatic cancer ,NK cells ,High glucose ,MICA/B ,Immune surveillance ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Modulation of cell surface expression of MHC class I chain-related protein A/B (MICA/B) has been proven to be one of the mechanisms by which tumor cells escape from NK cell-mediated killing. Abnormal metabolic condition, such as high glucose, may create a cellular stress milieu to induce immune dysfunction. Hyperglycemia is frequently presented in the majority of pancreatic cancer patients and is associated with poor prognosis. In this study, we aimed to detect the effects of high glucose on NK cell-mediated killing on pancreatic cancer cells through reduction of MICA/B expression. Methods The lysis of NK cells on pancreatic cancer cells were compared at different glucose concentrations through lactate dehydrogenase release assay. Then, qPCR, Western Blot, Flow cytometry and Immunofluorescence were used to identify the effect of high glucose on expression of MICA/B, Bmi1, GATA2, phosphorylated AMPK to explore the underlying mechanisms in the process. Moreover, an animal model with diabetes mellitus was established to explore the role of high glucose on NK cell-mediated cytotoxicity on pancreatic cancer in vivo. Results In our study, high glucose protects pancreatic cancer from NK cell-mediated killing through suppressing MICA/B expression. Bmi1, a polycomb group (PcG) protein, was found to be up-regulated by high glucose, and mediated the inhibition of MICA/B expression through promoting GATA2 in pancreatic cancer. Moreover, high glucose inhibited AMP-activated protein kinase signaling, leading to high expression of Bmi1. Conclusion Our findings identify that high glucose may promote the immune escape of pancreatic cancer cells under hyperglycemic tumor microenvironment. In this process, constitutive activation of AMPK-Bmi1-GATA2 axis could mediate MICA/B inhibition, which may serve as a therapeutic target for further intervention of pancreatic cancer immune evasion.
- Published
- 2019
- Full Text
- View/download PDF
9. The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study
- Author
-
Wenming Wu, MD, Gang Jin, MD, Chunyou Wang, MD, Yi Miao, MD, Huaizhi Wang, MD, Wenhui Lou, MD, Xianjun Yu, MD, Bei Sun, MD, Haimin Li, MD, Renyi Qin, MD, Zheng Wu, MD, Weilin Wang, MD, Kesen Xu, MD, Lei Wang, MD, Tingbo Liang, MD, Chunyi Hao, MD, Heguang Huang, MD, Yixiong Li, MD, Guang Tan, MD, Yongfu Zhao, MD, Jihui Hao, MD, Yifan Wang, MD, Chenghong Peng, MD, Xubao Liu, MD, Jinrui Ou, MD, Chunhui Yuan, MD, Xuefeng Wang, MD, Yinmo Yang, MD, Shouwang Cai, MD, Kejian Guo, MD, Jianxin Jiang, MD, Xiao Yu, MD, Junmin Wei, MD, Fei Li, MD, Xinmin Wu, MD, Yupei Zhao, MD, and and Pancreatic Surgery Study Group of Chinese Society of Surgery of Chinese Medical Association
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract. Objective:. The aim of this study is to investigate the current status of pancreatic cancer patients undoing surgical treatment in China and to find ways to improve the survival of these patients in the future. Methods:. This study is a national, multicenter, cross-sectional study in China. Information regarding pancreatic cancer patients undergoing surgical treatment from 34 high-volume tertiary IIIA level hospitals was collected and analyzed from the March 1, 2016 to the February 28, 2017. Results:. In total, 2200 pancreatic cancer patients were enrolled from 34 tertiary IIIA level hospitals in 16 provinces across China. The male-to-female ratio was 1.5. More than 80% of the patients were between 50 and 70 years old. The top 4 symptoms were epigastric discomfort, abdominal pain, jaundice, and weight loss. Carbohydrate antigen 19-9 and carcinoembryonic antigen were elevated in 70.9% and 27.1% of patients, respectively. A multidisciplinary team (MDT) discussion was carried out for 35.0% of patients before surgery. The proportion of minimally invasive pancreatic surgeries was approximately 20%. A total of 83.4% of the operations achieved R0 resection, and the incidence of grade 3/4 postoperative complications was 7.7%. Only 13.4% of the patients received postoperative adjuvant chemotherapy. The percentage of pathological stage I tumors was only 24.5%. Conclusion:. The majority of pancreatic cancer patients undergoing surgical resection in China are in an advanced stage. The MDT consultations for pancreatic cancer have not been widely carried out. R0 resection has been achieved in most cases, with relatively low incidence of serious complications, but minimally invasive pancreatic surgery should be further promoted. The application of postoperative chemotherapy remains low. This national, multicentre, cross-sectional study comprehensively presents the current status of pancreatic cancer patients undergoing surgical treatment and shows the road to improve survival of these patients in the future.
- Published
- 2019
- Full Text
- View/download PDF
10. A Chinese consensus statement on the diagnosis and treatment of pancreatic exocrine insufficiency after pancreatic surgery (2018)
- Author
-
Taiping Zhang, MD, Zhe Cao, MD, Rufu Chen, MD, Yiqi Du, MD, Defei Hong, MD, Kuirong Jiang, MD, Gang Jin, MD, Fei Li, MD, Weiqin Li, MD, Zhaoshen Li, MD, Tingbo Liang, MD, Quan Liao, MD, Wenhui Lou, MD, Yi Miao, MD, Jiaming Qian, MD, Renyi Qin, MD, Bei Sun, MD, Zhaohui Tang, MD, Chunyou Wang, MD, Weilin Wang, MD, Wenming Wu, MD, Yinmo Yang, MD, Gang Zhao, MD, Yupei Zhao, MD, and Study Group of Pancreatic Surgery in Chinese Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of Chinese Research Hospital Association
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract. A consensus statement on the diagnosis and treatment of pancreatic exocrine insufficiency (PEI) after pancreatic surgery was developed based on the latest references, combined with China's actual situation. More than 20 Chinese excellent experts participated in this work and contributed many thorough discussions. This consensus discusses the definition, epidemiology, diagnosis, treatment, and follow-up of PEI after pancreatic surgery. The authors hope this consensus will promote the standard procedure of diagnosis and treatment of PEI in China.
- Published
- 2018
- Full Text
- View/download PDF
11. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis
- Author
-
Xiaogang Li, Shanmiao Gou, Zhiqiang Liu, Zeng Ye, and Chunyou Wang
- Subjects
AJCC ,ENETS ,pancreatic neuroendocrine tumors ,prognosis ,staging system ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Although several staging systems have been proposed for pancreatic neuroendocrine tumors (pNETs), the optimal staging system remains unclear. Here, we aimed to assess the application of the newly revised 8th edition American Joint Committee on Cancer (AJCC) staging system for exocrine pancreatic carcinoma (EPC) to pNETs, in comparison with that of other staging systems. We identified pNETs patients from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2014). Overall survival was analyzed using Kaplan–Meier curves with the log‐rank test. The predictive accuracy of each staging system was assessed by the concordance index (c‐index). Cox proportional hazards regression was conducted to calculate the impact of different stages. In total, 2424 patients with pNETs, including 2350 who underwent resection, were identified using SEER data. Patients with different stages were evenly stratified based on the 8th edition AJCC staging system for EPC. Kaplan–Meier curves were well separated in all patients and patients with resection using the 8th edition AJCC staging system for EPC. Moreover, the hazard ratio increased with worsening disease stage. The c‐index of the 8th edition AJCC staging system for EPC was similar to that of the other systems. For pNETs patients, the 8th edition AJCC staging system for EPC exhibits good prognostic discrimination among different stages in both all patients and those with resection.
- Published
- 2018
- Full Text
- View/download PDF
12. Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis
- Author
-
Yushun Zhang, Feng Guo, Shoukang Li, Feiyang Wang, Zibo Meng, Jingyuan Zhao, Zhiqiang Liu, Bo Wang, Ping Fan, Chunyou Wang, and Heshui Wu
- Subjects
Medicine ,Science - Abstract
Abstract High density lipoprotein cholesterol (HDL-C) has been reported as a significant indicator of systemic inflammation. The association underlying HDL-C and persistent organ failure (POF), pancreatic necrosis (PNec) and mortality in acute pancreatitis (AP) has not been evaluated. From 2007 to 2016, consecutive AP patients with admission lipid profiles assessment were included in this study. The association of HDL-C value and other lipids with outcomes was explored with Cox proportional regression models, which were adjusted for confounding factors. 1131 consecutive AP patients were clinically eligible. Overall, 17.9% of the patients developed with POF, 27.1% experienced PNec, and 6.7% died during hospitalization. Lower HDL-C median (
- Published
- 2017
- Full Text
- View/download PDF
13. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
- Author
-
Xiaogang Li, Tong Li, Zhiqiang Liu, Shanmiao Gou, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
Abstract We conducted a meta-analysis to analyse the effect of metformin on survival of pancreatic cancer patients at various stages. We performed a systematic search of PubMed, Embase, Cochrane, and Web of Science to identify all relevant studies. Summary hazard ratios (HR) of survival and 95% confidence intervals (95% CI) were calculated with a fixed or random effects model according to inter-study heterogeneity. Nine retrospective cohort studies and two randomized controlled trials (RCTs) were eligible. There was a significant improvement in survival (HR = 0.86, 95% CI 0.76–0.97; P 0.05), or were excluded (HR = 0.89, 95% CI 0.61–1.31; P > 0.05). This meta-analysis indicated that the effect of metformin does correlate with tumor stage but should be prudently considered given the limited and variable studies performed to data.
- Published
- 2017
- Full Text
- View/download PDF
14. Chronic pancreatitis located in the pancreatic duct of a 23-year-old patient - What can be done?
- Author
-
Soriba Naby Camara, Ramdany Sonam, Sadamoudou Traore, Yin Tao, Ibrahima Sory Souare, Ahmed Boubacar Barry, Omar Banafei, Oumar Taibata Balde,, Ibrahima Sanoh, Qu Jing Chen, Jing Tao, Xiang Li, Yang Ming, Qin Qi, Dong Li Ming, Cui Jing, Huang Ming, He-Shui Wu, and Chunyou Wang
- Subjects
Chronic pancreatitis ,young patient ,pancreatic duct ,Surgery ,RD1-811 - Abstract
The aim of the study was to focus attention on the age of the young man under investigation. The onset age of chronic pancreatitis normally ranges from 30-40 years old. However, a young Chinese patient of just 23-years-old underwent an operation in order to treat chronic pancreatitis caused by stones and its post-operative outcome determined with the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). [Arch Clin Exp Surg 2016; 5(4.000): 233-237]
- Published
- 2016
- Full Text
- View/download PDF
15. Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine
- Author
-
Gang Zhao, Chunyou Wang, Zhiyong Yang, Tao Yin, Shanmiao Gou, Pengfei Shi, and Hongji Wei
- Subjects
pancreatic cancer ,Bmi-1 ,chemoresistance ,invasion ,tumorigenesis ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Pancreatic cancer is one of the most lethal malignancies with poor prognosis. Previously, we found that a subpopulation of cancer stem cells (CSCs) in the Panc-1 pancreatic cancer cell line could propagate to form spheres. Here we characterized the malignant phenotypes of the pancreatic cancer stem CD44+/CD24+ cells, which were enriched under sphere forming conditions as analyzed by flow cytometry. These cells demonstrated increased resistance to gemcitabine and increased migration ability. Moreover, these cells exhibited epithelial to mesenchymal transition characterized by a decreased level of the epithelial marker E-cadherin and an increased level of the mesenchymal marker vimentin. Notably, abnormal expression of Bmi-1, ABCG2, Cyclin D1 and p16 were found in Panc-1 CSCs. Our results suggest that targeted inhibition of CSCs represents a novel therapeutic approach to overcome chemoresistance and metastasis of pancreatic cancer.
- Published
- 2011
- Full Text
- View/download PDF
16. Prediction of Severe Acute Pancreatitis Using a Decision Tree Model Based on the Revised Atlanta Classification of Acute Pancreatitis.
- Author
-
Zhiyong Yang, Liming Dong, Yushun Zhang, Chong Yang, Shanmiao Gou, Yongfeng Li, Jiongxin Xiong, Heshui Wu, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
ObjectiveTo develop a model for the early prediction of severe acute pancreatitis based on the revised Atlanta classification of acute pancreatitis.MethodsClinical data of 1308 patients with acute pancreatitis (AP) were included in the retrospective study. A total of 603 patients who were admitted to the hospital within 36 hours of the onset of the disease were included at last according to the inclusion criteria. The clinical data were collected within 12 hours after admission. All the patients were classified as having mild acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP) based on the revised Atlanta classification of acute pancreatitis. All the 603 patients were randomly divided into training group (402 cases) and test group (201 cases). Univariate and multiple regression analyses were used to identify the independent risk factors for the development of SAP in the training group. Then the prediction model was constructed using the decision tree method, and this model was applied to the test group to evaluate its validity.ResultsThe decision tree model was developed using creatinine, lactate dehydrogenase, and oxygenation index to predict SAP. The diagnostic sensitivity and specificity of SAP in the training group were 80.9% and 90.0%, respectively, and the sensitivity and specificity in the test group were 88.6% and 90.4%, respectively.ConclusionsThe decision tree model based on creatinine, lactate dehydrogenase, and oxygenation index is more likely to predict the occurrence of SAP.
- Published
- 2015
- Full Text
- View/download PDF
17. Inverted U-Shaped Relationship between Central Venous Pressure and Intra-Abdominal Pressure in the Early Phase of Severe Acute Pancreatitis: A Retrospective Study.
- Author
-
Chong Yang, Zhiyong Yang, Xinglin Chen, Tao Liu, Shanmiao Gou, Changzhong Chen, Jun Xiao, Xin Jin, Zhiqiang He, Liming Dong, Yushun Zhang, Na Luo, Heshui Wu, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
ObjectiveMany studies have indicated that intra-abdominal pressure (IAP) is positively correlated with central venous pressure (CVP) in severe cases. However, although elevated IAP is common in patients with severe acute pancreatitis (SAP), its relationship with CVP remains unclear. Our study aimed to investigate the association of IAP with CVP in early-phase SAP patients.MethodsIn total, 116 SAP patients were included in this retrospective study. On the first day of hospitalization, blood samples were collected for biochemical examination and cytokine concentration monitoring. Additionally, a urinary catheter and right subclavian vein catheter were inserted for IAP and CVP measurement, respectively. Other routine clinical data were also recorded.ResultsWithin 24 hours after hospitalization, CVP fluctuated and increased with increasing IAP up to 15.7 mmHg (P = 0.054) but decreased with increasing IAP when the IAP was > 15.7 mmHg (P < 0.001). After adjusting for abdominal perfusion pressure (APP) and mean arterial pressure (MAP), a similar distribution was observed. An inverted U-shaped trend between IAP and CVP was also present in the groups classified according to the patient's sex, local complications, ascites, and serum amylase levels.ConclusionsCVP and IAP have an inverted U-shaped relationship, with a peak at an IAP of 15.7 mmHg in the early phase of SAP. After this peak, CVP decreases as IAP increases. These results have crucial implications for clinical fluid resuscitation in SAP patients. In particular, because one CVP value might be correlated with different IAP values in patients with the same CVP, the volume of fluid needed might be different.
- Published
- 2015
- Full Text
- View/download PDF
18. The Reduction of Peripheral Blood CD4+ T Cell Indicates Persistent Organ Failure in Acute Pancreatitis.
- Author
-
Zhiyong Yang, Yushun Zhang, Liming Dong, Chong Yang, Shanmiao Gou, Tao Yin, Heshui Wu, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
ObjectiveFew data are available on the potential role of inflammatory mediators and T lymphocytes in persistent organ failure (POF) in acute pancreatitis (AP). We conducted a retrospective study to characterize their role in the progression of POF in AP.MethodsA total of 69 AP patients presented within 24 hours from symptom onset developing organ failure (OF) on admission were included in our study. There were 39 patients suffering from POF and 30 from transient OF (TOF). On the 1st, 3rd and 7th days after admission, blood samples were collected for biochemical concentration monitoring including serum IL-1β, IL-6, TNF-α and high-sensitivity C-reactive protein (hs-CRP). The proportions of peripheral CD4(+) and CD8(+) T lymphocytes were assessed based on flow cytometry simultaneously.ResultsPatients with POF showed a significantly higher value of IL-1β and hs-CRP on day 7 compared with the group of TOF (P < 0.05). Proportions of CD4(+) T cells on days 1, 3, 7 and CD4(+)/ CD8(+) ratio on day 1 were statistically lower in the group of POF patients (P < 0.05). A CD4(+) T cell proportion of 30.34% on day 1 predicted POF with an area under the curve (AUC) of 0.798, a sensitivity with 61.54% and specificity with 90.00%, respectively.ConclusionsThe reduction of peripheral blood CD4(+) T lymphocytes is associated with POF in AP, and may act as a potential predictor.
- Published
- 2015
- Full Text
- View/download PDF
19. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro.
- Author
-
Tao Yin, Pengfei Shi, Shanmiao Gou, Qiang Shen, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
According to the cancer stem cells (CSCs) theory, malignant tumors may be heterogeneous in which a small population of CSCs drive the progression of cancer. Because of their intrinsic abilities, CSCs may survive a variety of treatments and then lead to therapeutic resistance and cancer recurrence. Pancreatic CSCs have been reported to be responsible for the malignant behaviors of pancreatic cancer, including suppression of immune protection. Thus, development of immune strategies to eradicate pancreatic CSCs may be of great value for the treatment of pancreatic cancer. In this study, we enriched pancreatic CSCs by culturing Panc-1 cells under sphere-forming conditions. Panc-1 CSCs expressed low levels of HLA-ABC and CD86, as measured by flow cytometry analysis. We further found that the Panc-1 CSCs modulate immunity by inhibiting lymphocyte proliferation which is promoted by phytohemagglutinin (PHA) and anti-CD3 monoclonal antibodies. The monocyte derived dendritic cells (DCs) were charged with total lysates generated from Panc-1 CSCs obtained from tumor sphere culturing. After co-culturing with lymphocytes at different ratios, the Panc-1 CSCs lysates modified DC effectively promoted lymphocyte proliferation. The activating efficiency reached 72.4% and 74.7% at the ratios of 1∶10 and 1∶20 with lymphocytes. The activated lymphocytes secreted high levels of INF-γ and IL-2, which are strong antitumor cytokines. Moreover, Panc-1 CSCs lysates modified DC induced significant cytotoxic effects of lymphocytes on Panc-1 CSCs and parental Panc-1 cells, respectively, as shown by lactate dehydrogenase (LDH) assay. Our study demonstrates that the development of CSCs-based vaccine is a promising strategy for treating pancreatic cancer.
- Published
- 2014
- Full Text
- View/download PDF
20. Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.
- Author
-
Shanmiao Gou, Pengfei Cui, Xiangsheng Li, Pengfei Shi, Tao Liu, and Chunyou Wang
- Subjects
Medicine ,Science - Abstract
Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States. The prognosis remains dismal with little advance in treatment. Metformin is a drug widely used for the treatment of type II diabetes. Recent epidemiologic data revealed that oral administration of metformin is associated with a reduced risk of pancreatic cancer, suggesting its potential as a novel drug for this disease. Many studies have demonstrated the in vitro anticancer action of metformin, but the typically used concentrations were much higher than the in vivo plasma and tissue concentrations achieved with recommended therapeutic doses of metformin, and low concentrations of metformin had little effect on the proliferation of pancreatic cancer cells. We examined the effect of low concentrations of metformin on different subpopulations of pancreatic cancer cells and found that these selectively inhibited the proliferation of CD133⁺ but not CD24⁺CD44⁺ESA⁺ cells. We also examined the effect of low concentrations of metformin on cell invasion and in vivo tumor formation, demonstrating in vitro and in vivo anticancer action. Metformin was associated with a reduction of phospho-Erk and phospho-mTOR independent of Akt and AMPK phosphorylation. CD133⁺ pancreatic cancer cells are considered to be cancer stem cells that contribute to recurrence, metastasis and resistance to adjuvant therapies in pancreatic cancer. Our results provide a basis for combination of metformin with current therapies to improve the prognosis of this disease.
- Published
- 2013
- Full Text
- View/download PDF
21. Nonlinear optical microscopy for histology of fresh normal and cancerous pancreatic tissues.
- Author
-
Wenyan Hu, Gang Zhao, Chunyou Wang, Jungang Zhang, and Ling Fu
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Pancreatic cancer is a lethal disease with a 5-year survival rate of only 1-5%. The acceleration of intraoperative histological examination would be beneficial for better management of pancreatic cancer, suggesting an improved survival. Nonlinear optical methods based on two-photon excited fluorescence (TPEF) and second harmonic generation (SHG) of intrinsic optical biomarkers show the ability to visualize the morphology of fresh tissues associated with histology, which is promising for real-time intraoperative evaluation of pancreatic cancer. METHODOLOGY/PRINCIPAL FINDINGS: In order to investigate whether the nonlinear optical imaging methods have the ability to characterize pancreatic histology at cellular resolution, we studied different types of pancreatic tissues by using label-free TPEF and SHG. Compared with other routine methods for the preparation of specimens, fresh tissues without processing were found to be most suitable for nonlinear optical imaging of pancreatic tissues. The detailed morphology of the normal rat pancreas was observed and related with the standard histological images. Comparatively speaking, the preliminary images of a small number of chemical-induced pancreatic cancer tissues showed visible neoplastic differences in the morphology of cells and extracellular matrix. The subcutaneous pancreatic tumor xenografts were further observed using the nonlinear optical microscopy, showing that most cells are leucocytes at 5 days after implantation, the tumor cells begin to proliferate at 10 days after implantation, and the extracellular collagen fibers become disordered as the xenografts grow. CONCLUSIONS/SIGNIFICANCE: In this study, nonlinear optical imaging was used to characterize the morphological details of fresh pancreatic tissues for the first time. We demonstrate that it is possible to provide real-time histological evaluation of pancreatic cancer by the nonlinear optical methods, which present an opportunity for the characterization of the progress of spontaneous pancreatic cancer and further application in a non-invasive manner.
- Published
- 2012
- Full Text
- View/download PDF
22. Data from LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
- Author
-
Gang Zhao, Chunyou Wang, Yong Zhao, Fan Wang, Jiang Tang, Zhu Zeng, Kang Huang, Chi He, Ding Chen, Ping Hu, Yuhang Hu, Yi Niu, Qingyong Chen, Mengqi Huang, and Fengyu Xu
- Abstract
Gemcitabine (GEM) resistance is a major challenge for chemotherapy of pancreatic cancer. Previous studies have reported on the role of long noncoding RNA (lncRNA) in tumorigenesis of pancreatic cancer, however, the involvement of lncRNA in the development of GEM resistance of pancreatic cancer remains unclear. In the present study, we demonstrated that the antisense RNA1 of HIF1α (HIF1A-AS1) was significantly elevated in the GEM-resistant pancreatic cancer cells. Gain- and lost-of-function experiments validated that HIF1A-AS1 promoted GEM resistance of pancreatic cancer cells both in vitro and vivo. We further revealed that HIF1A-AS1 upregulated HIF1α expression and thus promoted glycolysis to enhance GEM resistance of pancreatic cancer cells. Mechanistically, HIF1A-AS1 facilitated the interaction between serine/threonine kinase AKT and Y-box–binding protein 1 (YB1), which promoted phosphorylation of YB1 (pYB1). Meanwhile, HIF1A-AS1 recruited pYB1 to HIF1α mRNA that consequently promoted translation of HIF1α. Furthermore, HIF1α promoted HIF1A-AS1 transcription by directly binding to the HIF1α response element in the promoter area of HIF1A-AS1 to form a positive feedback. Consistently, both HIF1A-AS1 and HIF1α were upregulated in pancreatic cancer tissues and associated with poor overall survival. Together, our results underline a reciprocal loop of HIF1A-AS1 and HIF1α that contributes to GEM resistance of pancreatic cancer and indicate that HIF1A-AS1 might serve as a novel therapeutic target for GEM resistance of pancreatic cancer.Significance:These findings show that a reciprocal feedback of HIF1A-AS1 and HIF1α promotes gemcitabine resistance of pancreatic cancer, which provides an applicable therapeutic target.
- Published
- 2023
23. Supplementary Methods from LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
- Author
-
Gang Zhao, Chunyou Wang, Yong Zhao, Fan Wang, Jiang Tang, Zhu Zeng, Kang Huang, Chi He, Ding Chen, Ping Hu, Yuhang Hu, Yi Niu, Qingyong Chen, Mengqi Huang, and Fengyu Xu
- Abstract
Supplementary Methods
- Published
- 2023
24. Data from Nutrient Stress–Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression
- Author
-
Gang Zhao, Chunyou Wang, Yang Liu, Qiang Li, Feng-Yu Xu, Jian-Xin Zhong, Kang Huang, Ming-Liang Liu, Chi He, Zeng Ye, Shuai Zhu, Shichang Deng, Zhu Zeng, Heng-Yu Chen, and Shi-Jiang Deng
- Abstract
Cancer cells are known to undergo metabolic reprogramming, such as glycolysis and glutamine addiction, to sustain rapid proliferation and metastasis. It remains undefined whether long noncoding RNAs (lncRNA) coordinate the metabolic switch in pancreatic cancer. Here we identify a nuclear-enriched antisense lncRNA of glutaminase (GLS-AS) as a critical regulator involved in pancreatic cancer metabolism. GLS-AS was downregulated in pancreatic cancer tissues compared with noncancerous peritumor tissues. Depletion of GLS-AS promoted proliferation and invasion of pancreatic cancer cells both in vitro and in xenograft tumors of nude mice. GLS-AS inhibited GLS expression at the posttranscriptional level via formation of double stranded RNA with GLS pre-mRNA through ADAR/Dicer-dependent RNA interference. GLS-AS expression was transcriptionally downregulated by nutrient stress–induced Myc. Conversely, GLS-AS decreased Myc expression by impairing the GLS-mediated stability of Myc protein. These results imply a reciprocal feedback loop wherein Myc and GLS-AS regulate GLS overexpression during nutrient stress. Ectopic overexpression of GLS-AS inhibited proliferation and invasion of pancreatic cancer cells by repressing the Myc/GLS pathway. Moreover, expression of GLS-AS and GLS was inversely correlated in clinical samples of pancreatic cancer, while low expression of GLS-AS was associated with poor clinical outcomes. Collectively, our study implicates a novel lncRNA-mediated Myc/GLS pathway, which may serve as a metabolic target for pancreatic cancer therapy, and advances our understanding of the coupling role of lncRNA in nutrition stress and tumorigenesis.Significance: These findings show that lncRNA GLS-AS mediates a feedback loop of Myc and GLS, providing a potential therapeutic target for metabolic reprogramming in pancreatic cancer.See related commentary by Mafra and Dias, p. 1302
- Published
- 2023
25. Supplementary Figures from LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
- Author
-
Gang Zhao, Chunyou Wang, Yong Zhao, Fan Wang, Jiang Tang, Zhu Zeng, Kang Huang, Chi He, Ding Chen, Ping Hu, Yuhang Hu, Yi Niu, Qingyong Chen, Mengqi Huang, and Fengyu Xu
- Abstract
Supplementary Figures
- Published
- 2023
26. Supplementary Data from Nutrient Stress–Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression
- Author
-
Gang Zhao, Chunyou Wang, Yang Liu, Qiang Li, Feng-Yu Xu, Jian-Xin Zhong, Kang Huang, Ming-Liang Liu, Chi He, Zeng Ye, Shuai Zhu, Shichang Deng, Zhu Zeng, Heng-Yu Chen, and Shi-Jiang Deng
- Abstract
Supplementary Figure S1. Downregulation of GLS-AS facilitates pancreatic cancer proliferation and invasion. Supplementary Figure S2. Downregulation of GLS-AS apparently increased the GLS expression. Supplementary Figure S3. GLS-AS exert its biological function mainly through GLS. Supplementary Figure S4. The transcriptional activity of GLS promoter is not affected by GLS-AS. Supplementary Figure S5. GLS-AS inhibits GLS expression by ADAR1/Dicer-dependent RNA silencing in PANC-1 cells. Supplementary Figure S6. GLS-AS inhibits GLS expression via ADAR1/Dicer-dependent RNA silencing in BxPC-3 cells. Supplementary Figure S7. GLS-AS inhibits GLS expression by ADAR1/Dicer-dependent RNA silencing in BxPC-3 cells. Supplementary Figure S8. Schematic diagram of RNA pulldown by MS2-GST. Supplementary Figure S9. ADAR1 and Dicer are not significantly varied in pancreatic cancer cells under glucose or glutamine deprivation. Supplementary Figure S10. Downregulation of GLS-AS in pancreatic cancer might attributed to energy stress through Myc-depending regulation. Supplementary Figure S11. GLS and GLS-AS level does not affect Myc mRNA expression in pancreatic cancer cells. Supplementary Figure S12. GLS-AS is conversely correlated with Myc and GLS expression in pancreatic cancer. Supplementary Figure S13. GLS-AS suppresses pancreatic cancer cell growth, invasion and migration in vitro. Supplementary Figure S14. GLS-AS inhibits the progression of the pancreatic cancer in vivo proven with PANC-1 cells. Supplementary Figure S15. GLS-AS inhibits the progression of the pancreatic cancer in vivo proven with BxPC-3 cells.
- Published
- 2023
27. Supplementary Tables from LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
- Author
-
Gang Zhao, Chunyou Wang, Yong Zhao, Fan Wang, Jiang Tang, Zhu Zeng, Kang Huang, Chi He, Ding Chen, Ping Hu, Yuhang Hu, Yi Niu, Qingyong Chen, Mengqi Huang, and Fengyu Xu
- Abstract
Supplementary Tables
- Published
- 2023
28. LncRNA H19 facilitates polarization of M1 phenotype macrophages via miR-145-5p/PAI-1 axis in mediating systemic lupus erythematosus
- Author
-
Chenglei Zhao, Yong Zhang, Junkai Guo, Juan Wang, Chunyou Wang, Zhiqiang Song, and Yi You
- Abstract
LncRNAs take extensive effects in immune cells to mediate various autoimmune diseases. However, its potential role in development of SLE remains uncertain. We screened out candidate lncRNA in exosomes from SLE patients and the healthy, and was further validated in mouse model by histological examinations in vivo. Additional morphological verification was exploited to validate its biological functions by construction of plasmids in vitro. H19 in serum exosomes of patients was escalated, and could also promote the proliferation and migration of macrophages. Additionally, H19 mainly recruited miR-145-5p and promotes the expression of downstream targeted protein PAI-1. It further promoted the release of SLE-associated proinflammatory factors via Jak2-STAT3 axis, and in turn facilitated the polarization of M1 macrophages. Our study uncovered a potential mechanism of lncRNA H19 in mediating macrophage polarization and leading to the release of proinflammatory factors, providing a new intervention target for treating SLE.
- Published
- 2022
29. Study of microbial huff-and-puff field test in Weixing oil field
- Author
-
Chunyou Wang
- Published
- 2022
30. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis
- Author
-
Mengqi Huang, Chunyou Wang, Fan Wang, Yi Niu, Ping Hu, Zhu Zeng, Ding Chen, Shengbo Han, Qing-Yong Chen, Peng Xu, Zeng Ye, Jinghuang Chen, Gang Zhao, Yuhang Hu, Chaojie Hu, Jiang Tang, Yong Zhao, Fengyu Xu, and Shuai Zhu
- Subjects
Cancer Research ,Gene knockdown ,Biology ,Hypoxia (medical) ,Exosomes ,Hypoxia-Inducible Factor 1, alpha Subunit ,medicine.disease ,Exosome ,Microvesicles ,Pancreatic Neoplasms ,Mice ,Downregulation and upregulation ,Drug Resistance, Neoplasm ,Pancreatic cancer ,Genetics ,medicine ,Transcriptional regulation ,Cancer research ,Animals ,Humans ,Glycolysis ,medicine.symptom ,Molecular Biology - Abstract
Research has indicated that hypoxia profoundly contributes to chemoresistance of pancreatic cancer (PC), while the precise mechanism has not been fully elucidated. In this study, we report a hypoxic exosomal circular RNA (circRNA)-mediated mechanism of conferred chemoresistance in PC cells. Gemcitabine (GEM) resistance was enhanced in normoxic PC cells incubated with exosomes derived from hypoxic PC cells. CircRNA microarray displayed that circZNF91 was remarkably increased in hypoxic exosomes of PC cells compared with normoxic exosomes. Overexpression of circZNF91 obviously stimulated chemoresistance in PC cells, while knockdown of circZNF91 retarded the hypoxic exosome-transmitted chemoresistance. Mechanistically, the hypoxic-induced exosomal circZNF91 transmitted into normoxic PC cells could competitively bind to miR-23b-3p, which deprives the inhibition of miR-23b-3p on expression of deacetylase Sirtuin1 (SIRT1). Consequently, the upregulated SIRT1 enhanced deacetylation-dependent stability of HIF-1α protein, leading to glycolysis and GEM chemoresistance of recipient PC cells. In addition, we revealed that the increased circZNF91 in hypoxic exosome was attributed to the transcriptional regulation by HIF-1α. Coincidently, transmission of hypoxic exosomes into subcutaneous xenografts in nude mice obviously facilitated the chemoresistance of transplanted PC tumor, which could be reversed by depletion of circZNF91 or upregulation of miR-23b-3p. Furthermore, clinical data showed that circZNF91 was significantly upregulated in PC tissues and correlated with overexpression of glycolytic enzymes and short overall survival time. Collectively, exosomal circZNF91 can function as a cargo mediating the signal transmission between hypoxic and normoxic tumor cells to promote GEM chemoresistance of PC and may potentially serve as a therapeutic target.
- Published
- 2021
31. A reciprocal feedback of Myc and lncRNA MTSS1-AS contributes to extracellular acidity-promoted metastasis of pancreatic cancer
- Author
-
Fengyu Xu, Kaifeng Fang, Jian-Xin Zhong, Peng Xu, Wei Li, Xiaoming Shuai, Yong Zhao, Jinhuang Chen, Gang Zhao, Chunyou Wang, Jiang Tang, Yuhang Hu, Chaojie Hu, Ding Chen, Ping Hu, Zhu Zeng, Zhi Fang, Mengqi Huang, Fan Wang, and Kailin Cai
- Subjects
0301 basic medicine ,Transcriptional Activation ,Medicine (miscellaneous) ,Down-Regulation ,Myc ,Proto-Oncogene Mas ,Metastasis ,Cell Line ,Feedback ,Proto-Oncogene Proteins c-myc ,03 medical and health sciences ,0302 clinical medicine ,Transcription (biology) ,Cell Movement ,Cell Line, Tumor ,Sense (molecular biology) ,medicine ,Extracellular ,metastasis ,Humans ,Neoplasm Metastasis ,Promoter Regions, Genetic ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,MTSS1-AS ,Cell Proliferation ,Chemistry ,Acidity ,Microfilament Proteins ,Myeloid zinc finger 1 ,RNA ,medicine.disease ,Long non-coding RNA ,LncRNA ,Neoplasm Proteins ,Up-Regulation ,Pancreatic Neoplasms ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,RNA, Long Noncoding ,Chromatin immunoprecipitation ,Research Paper - Abstract
Rationale: Previous studies have reported on the role of extracellular acidity in the metastasis of numerous cancers. However, the involvement of long noncoding RNA (lncRNA) in the extracellular acidity-induced cancer metastasis of pancreatic cancer (PC) remains unclear. Methods: Different expression levels of lncRNAs in PC cells under normal and acidic conditions were compared by RNA sequencing (RNA-seq). The effects of antisense lncRNA of metastasis suppressor 1 (MTSS1-AS) on acidic PC cells were assessed by gain- and loss-of-function experiments. Fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down, Western blot, luciferase reporter, and Chromatin immunoprecipitation assays were employed to determine the regulatory mechanisms of MTSS1-AS in the acidity-induced metastasis of PC cells. The expression of MTSS1-AS and associated pathways were compared in PC samples and peritumoral normal tissues. Results: RNA-seq demonstrated that MTSS1-AS was significantly downregulated in pancreatic cells cultured with the acidic medium. The overexpression of MTSS1-AS remarkably inhibited the acidity-promoted metastasis of PC cells by upregulating the expression of its sense gene metastasis suppressor 1 (MTSS1). Mechanistically, MTSS1-AS scaffolded the interaction between E3 ubiquitin-protein ligase STIP1 homology and U-box containing protein 1 (STUB1) and transcription regulator myeloid zinc finger 1 (MZF1), leading to ubiquitination-mediated degradation of MZF1. Further, MZF1 inhibited the expression of MTSS1 by binding to the MTSS1 promoter. Thus, the acidity-reduced MTSS1-AS facilitated the stability of MZF1 and its inhibitory effect on MTSS1 transcription, thereby promoting the metastasis of PC cells under acidic conditions. Moreover, MTSS1-AS was transcriptionally repressed by the binding of MYC proto-oncogene (Myc) with initiator (Inr) elements of the MTSS1-AS promoter. Meanwhile, MTSS1-AS mutually repressed the expression of Myc by impairing the MZF1-mediated transcription activation of Myc, thereby forming a negative feedback loop between MTSS1-AS and Myc in acidic PC cells. In accordance with the experimental results, MTSS1-AS and MTSS1 were downregulated in PC and correlated with poor overall survival. Conclusions: The results implicated that a reciprocal feedback loop between Myc and MTSS1-AS contributed to the extracellular acidity-promoted metastasis of PC, and indicated that MTSS1-AS was a valuable biomarker and therapeutic target for PC.
- Published
- 2020
32. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer
- Author
-
Chunyou Wang, Qingke Duan, Hengqiang Zhao, Tao Yin, Hehe Li, Qiang Shen, Shihong Wu, and Zhengle Zhang
- Subjects
0301 basic medicine ,AMPK ,cancer stem cells ,Cancer Research ,endocrine system diseases ,pancreatic cancer ,medicine.disease_cause ,chemotherapy ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,Pancreatic cancer ,medicine ,KRAS ,Pharmacology (medical) ,aerobic glycolysis ,biology ,Panca ,Chemistry ,Cancer ,ROS ,biology.organism_classification ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,Oncology ,Anaerobic glycolysis ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Molecular Medicine - Abstract
Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM). Glucose metabolism has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells. However, few studies have focused on the effects of GEM on cancer cell metabolism, stemness of tumor cells, and molecular mechanisms that critically influence PanCa treatment. We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidation and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells. Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM’s cytotoxicity. GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift. GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness. In addition, GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway. This effect was validated by introducing exogenous hydrogen peroxide (H2O2). Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment. Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients. Keywords: ROS, KRAS, AMPK, aerobic glycolysis, cancer stem cells, pancreatic cancer, chemotherapy
- Published
- 2019
33. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α
- Author
-
Shijiang Deng, Fengyu Xu, Gang Zhao, Jian-Xin Zhong, Hai Zheng, Yuhang Hu, Zhu Zeng, Wei Li, Qiang Li, Fan Wang, Zeng Ye, Ping Cheng, Chunyou Wang, Qing-Yong Chen, Mingliang Liu, and Kang Huang
- Subjects
0301 basic medicine ,Transcription, Genetic ,LncRNA-MTA2TR ,pancreatic cancer ,Activating transcription factor ,Medicine (miscellaneous) ,HIF-1α ,Mice, Nude ,medicine.disease_cause ,Histone Deacetylases ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Cell Line, Tumor ,Transcriptional regulation ,medicine ,Animals ,Humans ,ATF3 ,Neoplasm Invasiveness ,MTA2 ,Promoter Regions, Genetic ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Cell Proliferation ,Mice, Inbred BALB C ,Activating Transcription Factor 3 ,Cell growth ,Chemistry ,Protein Stability ,Acetylation ,Hypoxia-Inducible Factor 1, alpha Subunit ,Prognosis ,Long non-coding RNA ,Cell Hypoxia ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,Repressor Proteins ,030104 developmental biology ,030220 oncology & carcinogenesis ,Gene Knockdown Techniques ,Cancer research ,Disease Progression ,RNA, Long Noncoding ,Carcinogenesis ,Research Paper - Abstract
Rationale: Hypoxia has been proved to contribute to aggressive phenotype of cancers, while functional and regulatory mechanism of long noncoding RNA (lncRNA) in the contribution of hypoxia on pancreatic cancer (PC) tumorigenesis is incompletely understood. The aim of this study was to uncover the regulatory and functional roles for hypoxia-induced lncRNA-MTA2TR (MTA2 transcriptional regulator RNA, AF083120.1) in the regulation of PC tumorigenesis. Methods: A lncRNA microarray confirmed MTA2TR expression in tissues of PC patients. The effects of MTA2TR on proliferation and metastasis of PC cells and xenograft models were determined, and the key mechanisms by which MTA2TR promotes PC were further dissected. Furthermore, the expression and regulation of MTA2TR under hypoxic conditions in PC cells were assessed. We also assessed the correlation between MTA2TR expression and PC patient clinical outcomes. Results: We found that metastasis associated protein 2 (MTA2) transcriptional regulator lncRNA (MTA2TR) was overexpressed in PC patient tissues relative to paired noncancerous tissues. Furthermore, we found that depletion of MTA2TR significantly inhibited PC cell proliferation and invasion both in vitro and in vivo. We further demonstrated that MTA2TR transcriptionally upregulates MTA2 expression by recruiting activating transcription factor 3 (ATF3) to the promoter area of MTA2. Consequentially, MTA2 can stabilize the HIF-1α protein via deacetylation, which further activates HIF-1α transcriptional activity. Interestingly, our results revealed that MTA2TR is transcriptionally regulated by HIF-1α under hypoxic conditions. Our clinical samples further indicated that the overexpression of MTA2TR was correlated with MTA2 upregulation, as well as with reduced overall survival (OS) in PC patients. Conclusions: These results suggest that feedback between MTA2TR and HIF-1α may play a key role in regulating PC tumorigenesis, thus potentially highlighting novel avenues PC treatment.
- Published
- 2019
34. Abstract P1-11-11: Cimicifuga racemosa extract prevents menopausal syndrome in LHRHa treatment of breast cancer: A prospective randomized research
- Author
-
Houpu Yang, Xingfei Yu, Haojun Xuan, Chen Liang, and Chunyou Wang
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,Ovarian cyst ,business.industry ,Uterine fibroids ,Cancer ,Menopausal Syndrome ,medicine.disease ,Menopause ,Breast cancer ,Oncology ,Clinical endpoint ,medicine ,Luteinizing hormone ,business - Abstract
BACKGROUND Menopausal syndrome (MPS) is common in pre/peri-menopausal breast cancer patient receiving luteinizing-hormone releasing hormone analogue (LHRHa). According to the results of TEXT & SOFT study, it could affect patients' life quality seriously and even caused 8%˜23% treatment break. Cimicifuga racemosa (Remifemin) is previously proved effective for MPS in nature menopause patients. We aim to design a prospective randomized research for investigating the effect of Remifemin on MPS which caused by LHRHa in breast cancer (NCT03339882). METHODS The pre/peri-menopausal patients diagnosed as early breast cancer planning for LHRHa were identified and randomly divided into two groups after surgery and chemotherapy if necessary: the Remifemin group (Remifemin 20mg twice a day for 12 weeks) and the control group. The primary endpoint is Kupperman menopause index (KMI). The estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH) levels in blood were also evaluated. RESULTS From January 2017 to December 2017, totally 85 patients (42 in Remifemin group and 43 in control group) were enrolled in Zhejiang Cancer Hospital and there were no significant differences in baseline characteristics including age, BMI, tumor stage, ER, PR, HER2, KMI and hormone levels between two groups (Table 1). At the time of 4, 8, 12 weeks after treatment, the KMI of Remifenmin group were all significantly lower than control group (Table 2, P0.05).There was no significant difference in endometrial thickness, ovarian cyst and Uterine fibroids except cervical cyst (P=0.02). CONCLUSION The use of Remifemin is oncological safe and reliable in preventing MPS which caused by LHRHa in breast cancer. The clinical characteristics of two groups Remifemin groupControl groupP n=42n=43 N(%)N(%) Age(years) 37.74±6.6037.16±6.280.68BMI (body mass index) 21.90±2.8321.65±3.010.69T stage02(4.76)2 (4.65)0.16 113 (30.95)22 (51.16) 227 (64.29)19 (44.19) N stage021 (50.00)24 (55.82)0.63 110 (23.81)12 (27.91) 26 (14.29)5 (11.63) 35 (11.90)2 (4.65) ERPositive30 (71.43)35 (81.40)0.28 Negative12 (28.57)8 (18.60) PRPositive30 (71.43)32 (74.42)0.76 Negative12 (28.57)11 (25.58) HER2Positive8 (19.05)10 (23.26)0.64 Negative34 (80.95)33 (76.74) Category of LHRHaGoserelin32 (76.19)28 (65.12)0.26 Leuprorelin10 (23.81)15 (34.88) Category of endocrine drugNone10 (23.81)6 (13.95)0.20 SERM5 (11.90)11 (25.58) AI27 (64.29)26 (60.47) The endpoints of two groups Remifemin groupControl groupP n=42n=43 KMI*Base line2.45±1.452.30±1.360.62 4th week3.83±1.868.37±4.19 Citation Format: Yu X, Wang C, Liang C, Xuan H, Yang H. Cimicifuga racemosa extract prevents menopausal syndrome in LHRHa treatment of breast cancer: A prospective randomized research [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-11.
- Published
- 2019
35. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
- Author
-
Yong Zhao, Kang Huang, Fan Wang, Chunyou Wang, Jiang Tang, Ding Chen, Ping Hu, Fengyu Xu, Qing-Yong Chen, Gang Zhao, Yuhang Hu, Zhu Zeng, Yi Niu, Mengqi Huang, and Chi He
- Subjects
Male ,Cancer Research ,Antimetabolites, Antineoplastic ,Mice, Nude ,Apoptosis ,medicine.disease_cause ,Deoxycytidine ,Mice ,Downregulation and upregulation ,Pancreatic cancer ,medicine ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Animals ,Humans ,Neoplasm Invasiveness ,Protein kinase B ,Cell Proliferation ,Mice, Inbred BALB C ,Chemistry ,Kinase ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Prognosis ,Xenograft Model Antitumor Assays ,Gemcitabine ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,Survival Rate ,HIF1A ,Oncology ,Drug Resistance, Neoplasm ,Cancer research ,Phosphorylation ,RNA, Long Noncoding ,Y-Box-Binding Protein 1 ,Carcinogenesis ,Glycolysis ,Proto-Oncogene Proteins c-akt ,medicine.drug - Abstract
Gemcitabine (GEM) resistance is a major challenge for chemotherapy of pancreatic cancer. Previous studies have reported on the role of long noncoding RNA (lncRNA) in tumorigenesis of pancreatic cancer, however, the involvement of lncRNA in the development of GEM resistance of pancreatic cancer remains unclear. In the present study, we demonstrated that the antisense RNA1 of HIF1α (HIF1A-AS1) was significantly elevated in the GEM-resistant pancreatic cancer cells. Gain- and lost-of-function experiments validated that HIF1A-AS1 promoted GEM resistance of pancreatic cancer cells both in vitro and vivo. We further revealed that HIF1A-AS1 upregulated HIF1α expression and thus promoted glycolysis to enhance GEM resistance of pancreatic cancer cells. Mechanistically, HIF1A-AS1 facilitated the interaction between serine/threonine kinase AKT and Y-box–binding protein 1 (YB1), which promoted phosphorylation of YB1 (pYB1). Meanwhile, HIF1A-AS1 recruited pYB1 to HIF1α mRNA that consequently promoted translation of HIF1α. Furthermore, HIF1α promoted HIF1A-AS1 transcription by directly binding to the HIF1α response element in the promoter area of HIF1A-AS1 to form a positive feedback. Consistently, both HIF1A-AS1 and HIF1α were upregulated in pancreatic cancer tissues and associated with poor overall survival. Together, our results underline a reciprocal loop of HIF1A-AS1 and HIF1α that contributes to GEM resistance of pancreatic cancer and indicate that HIF1A-AS1 might serve as a novel therapeutic target for GEM resistance of pancreatic cancer. Significance: These findings show that a reciprocal feedback of HIF1A-AS1 and HIF1α promotes gemcitabine resistance of pancreatic cancer, which provides an applicable therapeutic target.
- Published
- 2021
36. Construction and expression of human PTEN tumor suppressor gene recombinant adenovirus vector
- Author
-
Qingyong, Chen, Chunyou, Wang, Daoda, Chen, Jianying, Chen, Chunfang, Jiang, and Hai, Zheng
- Published
- 2006
- Full Text
- View/download PDF
37. Reciprocal loop of hypoxia-inducible factor-1α (HIF-1α) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription
- Author
-
Chi He, Gang Zhao, Jian-Xin Zhong, Shijiang Deng, Zhu Zeng, Mingliang Liu, Zeng Ye, Heshui Wu, Shichang Deng, Shuai Zhu, Hengyu Chen, and Chunyou Wang
- Subjects
0301 basic medicine ,Gene knockdown ,Cadherin ,Biology ,medicine.disease ,HDAC1 ,Pathology and Forensic Medicine ,Metastasis ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Downregulation and upregulation ,Hypoxia-inducible factors ,Transcription (biology) ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,MTA2 - Abstract
Metastasis-associated protein 2 (MTA2) is overexpressed in certain malignancies, and plays important roles in tumour metastasis and progression. The present study highlights the function of MTA2 in pancreatic carcinoma through its role as a deacetylator of hypoxia-inducible factor-1α (HIF-1α) and a cotranscriptional factor for E-cadherin expression. We found that overexpression of MTA2 promoted, and knockdown of MTA2 inhibited, the invasion and proliferation of pancreatic carcinoma cells both in vitro and in xenograft models in vivo. We also found that MTA2 is transcriptionally upregulated by HIF-1α through a hypoxia response element (HRE) of the MTA2 promoter in response to hypoxia. Reciprocally, MTA2 deacetylates HIF-1α and enhances its stability through interacting with histone deacetylase 1 (HDAC1). Consequently, HIF-1α recruits MTA2 and HDAC1 to the HRE of the E-cadherin promoter, by which E-cadherin transcription is repressed. In agreement with these experimental results, MTA2 is positively associated with HIF-1α, but inversely correlated with E-cadherin, in pancreatic carcinoma samples. Moreover, data from The Cancer Genome Atlas on 172 pancreatic carcinomas indicate an association between high expression of MTA2 and short overall survival. Taken together, our study identifies MTA2 as a critical hub and potential therapeutic target to inhibit the progression and metastasis of pancreatic carcinoma. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Published
- 2018
38. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data
- Author
-
Shanmiao Gou, Zhiqiang Liu, Zeng Ye, Chunyou Wang, and Xiaogang Li
- Subjects
Male ,Oncology ,Aging ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,03 medical and health sciences ,0302 clinical medicine ,Pancreatic cancer ,Internal medicine ,Epidemiology ,Humans ,Medicine ,Aged ,Retrospective Studies ,Aged, 80 and over ,Pancreatic duct ,Hepatology ,business.industry ,Proportional hazards model ,Hazard ratio ,Gastroenterology ,Middle Aged ,medicine.disease ,Survival Analysis ,Confidence interval ,Surgery ,Cancer registry ,Pancreatic Neoplasms ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Adenocarcinoma ,Female ,030211 gastroenterology & hepatology ,business ,Carcinoma, Pancreatic Ductal ,SEER Program - Abstract
Background To explore the impact of age on all-cause death and cancer-specific death in patients with pancreatic duct adenocarcinoma (PDAC) undergoing surgery. Materials and methods Individuals with PDAC undergoing surgery between 2004 and 2013 (N = 11,138) were retrospectively studied from the Surveillance, Epidemiology, and End Results (SEER) cancer registry database. The impact of age on all-cause death and cancer-specific death was assessed using Cox regression model and competing risk model respectively. Results Multivariate Cox regression analysis indicated that the risks of all-cause death increased with age: hazard ratios (95% confidence interval, 95%CI) were 1.10 (1.04–1.17), 1.31 (1.23–1.38), 1.47 (1.35–1.61) for groups 61–70 years, 71–80 years, and >80 years, respectively, compared with ≤60 years. Multivariate competing risk analysis indicated that the risk of cancer-specific death was similar between patients ≤60 years and 61–70 years (subhazard ratio 0.93; 95% confidence interval 0.87–1.00), but decreased in patients 71–80 years (subhazard ratio 0.84; 95%CI 0.79–0.90) and >80 years (subhazard ratio 0.76; 95%CI 0.68–0.85). Conclusion Age at diagnosis appeared to be an independent predictor of prognosis, with reverse impacts on all-cause death and cancer-specific death.
- Published
- 2018
39. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis
- Author
-
Shanmiao Gou, Zhiqiang Liu, Chunyou Wang, Xiaogang Li, and Zeng Ye
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Neuroendocrine tumors ,ENETS ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,Surveillance, Epidemiology, and End Results ,staging system ,Humans ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Staging system ,AJCC staging system ,Original Research ,Aged ,Neoplasm Staging ,AJCC ,pancreatic neuroendocrine tumors ,business.industry ,Hazard ratio ,Cancer ,Clinical Cancer Research ,Middle Aged ,medicine.disease ,Prognosis ,United States ,Carcinoma, Neuroendocrine ,Pancreatic Neoplasms ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,business ,SEER Program - Abstract
Although several staging systems have been proposed for pancreatic neuroendocrine tumors (pNETs), the optimal staging system remains unclear. Here, we aimed to assess the application of the newly revised 8th edition American Joint Committee on Cancer (AJCC) staging system for exocrine pancreatic carcinoma (EPC) to pNETs, in comparison with that of other staging systems. We identified pNETs patients from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2014). Overall survival was analyzed using Kaplan–Meier curves with the log‐rank test. The predictive accuracy of each staging system was assessed by the concordance index (c‐index). Cox proportional hazards regression was conducted to calculate the impact of different stages. In total, 2424 patients with pNETs, including 2350 who underwent resection, were identified using SEER data. Patients with different stages were evenly stratified based on the 8th edition AJCC staging system for EPC. Kaplan–Meier curves were well separated in all patients and patients with resection using the 8th edition AJCC staging system for EPC. Moreover, the hazard ratio increased with worsening disease stage. The c‐index of the 8th edition AJCC staging system for EPC was similar to that of the other systems. For pNETs patients, the 8th edition AJCC staging system for EPC exhibits good prognostic discrimination among different stages in both all patients and those with resection.
- Published
- 2018
40. Effect of early hemofiltration on pro- and anti-inflammatory responses and multiple organ failure in severe acute pancreatitis
- Author
-
Zhiyong, Yang, Chunyou, Wang, Jing, Tao, Jiongxin, Xiong, Chidan, Wan, and Feng, Zhou
- Published
- 2004
- Full Text
- View/download PDF
41. Diagnosis and management of severe acute pancreatitis complicated with abdominal compartment syndrome
- Author
-
Jing, Tao, Chunyou, Wang, Libo, Chen, Zhiyong, Yang, Yiqing, Xu, Jiongqi, Xiong, and Feng, Zhou
- Published
- 2003
- Full Text
- View/download PDF
42. AB0762 THE CHARACTERISTICS OF PERIPHERAL LYMPHOCYTE SUBSETS IN PATIENTS WITH IGG4-RELATED DISEASE
- Author
-
Xuejiao Li, Chunyou Wang, R. Su, Y. Y. Wang, and Xuezhong Yu
- Subjects
Rheumatology ,business.industry ,Immunology ,medicine ,Immunology and Allergy ,IgG4-related disease ,In patient ,medicine.disease ,business ,General Biochemistry, Genetics and Molecular Biology ,Peripheral ,Lymphocyte subsets - Abstract
Background:Immunoglobulin G4-related disease (IgG4-RD) is an autoimmune disease with chronic systemic inflammation and fibrosis. The main feature of the disease was diffuse swell of the affected organs, and the serum IgG4 level was increased. Histopathology of the lesions showed infiltration of IgG4+ plasma cells. However, the pathogenesis of IgG4-RD is still unclear[1].Objectives:To explore the clinical characteristic of lymphocyte subsets of IgG4-related disease patients, and make comparisons with healthy controls.Methods:A total of 31 patients with IgG4-RD who were admitted to the Rheumatic Immunology Department of the Second Hospital of Shanxi Medical University from January 2016 to June 2020 were included. We collected their Clinical and laboratory data, and selected 30 age and sex matched healthy people as the control group. Flow cytometry was used to detect the percentage and absolute number of lymphocyte subsets (T, B, NK, CD4+T, CD8+T) and CD4+T subsets (Th1, Th2, Th17, CD4+CD25+Foxp3+Treg) in peripheral blood of IgG4-RD patients and healthy controls.Results:(1)The percentage of CD4+T cells in peripheral blood of IgG4-RD patients was higher than that of healthy controls [45.00(33.97-51.48) vs. 39.36(33.78-43.30), PTable 1.Comparation of absolute number and percentage of peripheral blood lymphocyte subsets between IgG4-RD patients(n=31) and healthy controls (n=30).cell subsetsIgG4-RD (n=31)HC(n=30)P valueB150.59(120.14-212.38)203.27(152.90-244.27)0.089B%8.74(6.46-11.45)10.03(8.26-13.21)0.059NK261.98(178.82-303.08)290.83(179.93-451.45)0.175NK%13.14(9.92-18.10)16.50(11.24-21.75)0.105CD3+T1357.44(992.00-1844.82)1305.81(978.24-1597.94)0.708 CD3+T%72.62(69.32-76.96)71.62(64.97-75.25)0.135CD8+T436.40(342.71-596.86)513.50(359.73-620.53)0.665CD8+T%24.26(19.48-31.27)26.50(20.67-32.90)0.535CD4+T741.00(562.78-1095.52)664.50(585.52-789.97)0.428CD4+T%45.00(33.97-51.48)39.36(33.78-43.30)0.032Th1162.32(108.11-216.61)144.27(81.52-161.66)0.094Th1%19.00(15.24-25.54)18.46(14.86-24.27)0.644Th27.82(5.35-11.78)8.25(5.32-10.87)0.817Th2%1.00(0.76-1.27)1.24(0.89-1.64)0.399Th177.90(5.20-12.23)5.60(3.12-8.47)0.010Th17%1.13(0.70-1.55)0.77(0.43-1.07)0.026Treg24.45(19.76-44.79)34.55(27.29-46.57)0.076Treg%3.37(2.82-5.65)4.96(4.18-6.34)0.003Th1/Th220.00(13.78-36.36)14.97(10.31-21.58)0.135Th1/Treg5.72(2.92-8.86)3.68(2.53-4.77)0.021Th2/Treg0.27(0.16-0.52)0.22(0.15-0.32)0.199Th17/Treg0.29(0.16-0.46)0.15(0.08-0.23)0.002Conclusion:Th17/Treg immune disorder exists in IgG4-RD patients, and it is related to the disease activity, indicating that Th17/Treg imbalance may be an important pathogenesis of IgG4-RD.References:[1]Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976): 1460-1471.Disclosure of Interests:None declared
- Published
- 2021
43. Serum calcium as an indicator of persistent organ failure in acute pancreatitis
- Author
-
Chunyou Wang, Tao Peng, Heshui Wu, Min Huang, Yushun Zhang, Xin Peng, and Jing Cui
- Subjects
Male ,China ,medicine.medical_specialty ,endocrine system diseases ,Multiple Organ Failure ,chemistry.chemical_element ,Calcium ,Logistic regression ,Severity of Illness Index ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,Severity of illness ,Humans ,Medicine ,Hospital Mortality ,Retrospective Studies ,business.industry ,Area under the curve ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Endotoxemia ,female genital diseases and pregnancy complications ,Endocrinology ,Pancreatitis ,chemistry ,030220 oncology & carcinogenesis ,Predictive value of tests ,Emergency Medicine ,Acute pancreatitis ,Female ,030211 gastroenterology & hepatology ,business ,Biomarkers - Abstract
Decreased level of serum calcium was commonly seen in critical illness. Hypocalcemia was significantly more frequent in patients with severe form of acute pancreatitis (AP), and a negative correlation was observed between endotoxemia and serum calcium in AP. AP patients with persistent organ failure (POF) show an extremely high mortality. The association underlying calcium and POF in AP has not been characterized.We conducted a retrospective cohort study of adult patients who presented within 72hours from symptom onset of AP at our center between January 2014 and May 2015. Demographic parameters on admission, organ failure assessment, laboratory data and in-hospital mortality were compared between patients with and without POF. Uni-and multi-variate logistic regression analyses were utilized to evaluated the predictive ability of serum calcium.A total of 128 consecutive AP patients, including 29 with POF, were included. Compared to patients without POF, patients with POF showed a significantly lower value of serum calcium on admission (2.11±0.46 vs. 1.55±0.36mmol/L, P0.001). After multivariate logistic analysis, serum calcium remained an independent risk factor for POF (Hazard ratio 0.21, 95% confident interval: 0.08-0.58; P=0.002). A calcium value of 1.97mmol/L predicted POF with an area under the curve (AUC) of 0.888, a sensitivity with 89.7% and specificity with 74.8%, respectively.Our results indicate that serum calcium on admission is independently associated with POF in AP and may serve as a potential prognostic factor.
- Published
- 2017
44. Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness
- Author
-
Chunyou Wang, Li Wang, Zhiyong Yang, Tao Peng, Wei Zhou, Feng Guo, and Heshui Wu
- Subjects
0301 basic medicine ,endocrine system diseases ,Carcinogenesis ,Science ,Cell Cycle Proteins ,medicine.disease_cause ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cyclin D1 ,Downregulation and upregulation ,Cell Line, Tumor ,medicine ,Humans ,Neoplasm Invasiveness ,RNA, Messenger ,Nuclear protein ,Multidisciplinary ,Chemistry ,NF-kappa B ,Nuclear Proteins ,Cell migration ,Prognosis ,NFKB1 ,Survival Analysis ,digestive system diseases ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,IκBα ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Medicine ,Signal Transduction - Abstract
Centrosomal protein 55 (CEP55) is a microtubule-bundling protein that participants in cell mitosis. It is overexpressed in several solid tumours and promotes the growth and invasion of cancer cells. However, the role of CEP55 in pancreatic cancer (PANC) remains unclear. Herein, upregulated expression of CEP55 (associated with poor prognosis) was detected in PANC using quantitative real-time reverse transcription PCR, western blotting, and immunohistochemistry. Cell migration, colony formation, wound-healing, and Transwell matrix penetration assays, revealed that upregulation of CEP55 promoted PANC cells proliferation, migration, and invasion in vitro, whereas knockdown of CEP55 attenuated it. In an in vivo murine model, CEP55 overexpression accelerated PANC cells tumourigenicity, together with upregulation of the protein levels of invasion-related proteins matrix metalloproteinase (MMP)2, MMP9, and proliferation-related protein Cyclin D1. Downregulation of CEP55 had the reverse effect. Moreover, the nuclear factor κB (NF-κB)/IκBα signalling pathway, which was activated in CEP55-transduced PANC cells and inhibited in CEP55-silenced PANC cells, contributed to CEP55-mediated PANC cell aggressiveness. This study provided new insights into the oncogenic roles of CEP55 and the mechanism by which the NF-κB pathway is hyperactivated in patients with PANC, indicating that CEP55 is a valuable prognostic factor and a potential therapeutic target in PANC.
- Published
- 2017
45. miR-532 promoted gastric cancer migration and invasion by targeting NKD1
- Author
-
Tao Liu, Shaobo Hu, Qichang Zheng, Heshui Wu, Chunyou Wang, and Wei Zhou
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Biology ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Stomach Neoplasms ,Cell Line, Tumor ,microRNA ,Gene Knockdown Techniques ,medicine ,Humans ,Neoplasm Invasiveness ,Luciferase ,General Pharmacology, Toxicology and Pharmaceutics ,Wnt Signaling Pathway ,Adaptor Proteins, Signal Transducing ,Gene knockdown ,Calcium-Binding Proteins ,Antagonist ,Wnt signaling pathway ,Cancer ,General Medicine ,medicine.disease ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Carrier Proteins ,Wound healing - Abstract
Gastric cancer is one of the most common human malignant neoplasms, especially in China, its regulatory mechanism is important to develop new therapy approaches. miRNAs have been demonstrated to regulate gastric cancer progression. We found miR-532 was overexpressed in gastric cancer tissues and cells. Wound healing and transwell assay revealed that its overexpression promoted gastric cancer cell migration and invasion, its knockdown inhibited gastric cancer cell migration and invasion. Wnt/β-catenin antagonist naked cuticle homolog 1 (NKD1) was the target of miR-532, miR-532 inhibited NKD1 expression. TOP/FOP luciferase activity analysis suggested miR-532 also increased Wnt/β-catenin pathway activity. Overexpression miR-532 and NKD1 inhibited gastric cancer cell migration and invasion, consistent with miR-532 knockdown. These findings revealed miR-532 promoted gastric cancer cell migration and invasion through inhibiting NKD1 and activated Wnt/β-catenin pathway. We provide a potential target for gastric cancer therapy.
- Published
- 2017
46. CT-guided Drainage of Deep Pelvic Abscesses via a Percutaneous Presacral Space Approach
- Author
-
Liming Dong, Tao Peng, Qian Li, Zhiyong Yang, Zhihua Zhu, Xin Li, Chunyou Wang, Jing Cui, and Heshui Wu
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,Anastomosis ,Dehiscence ,medicine.disease ,Appendicitis ,030218 nuclear medicine & medical imaging ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Tolerability ,030220 oncology & carcinogenesis ,medicine ,Presacral space ,Radiology, Nuclear Medicine and imaging ,Radiology ,Drainage ,business ,Pelvis - Abstract
Rationale and Objectives Some deep pelvic abscesses are not accessible through anterior or lateral approaches because of the presence of organs and structures. The objective of this study was to assess the feasibility, safety, tolerability, and efficacy of a percutaneous presacral space approach by reviewing our clinical experience and the literature. Materials and Methods The outcomes of 12 patients, who have undergone computed tomography (CT)-guided percutaneous presacral space drainage, were retrospectively reviewed, including demographic, clinical, and morphological data in the medical records. Results From August 2010 to June 2015, 98 patients underwent CT-guided percutaneous drainage of pelvis abscesses in our institution. A percutaneous presacral space approach was adopted in 12 cases. The fluid collections were related to postoperative complications in nine patients (75%) and inflammatory or infectious intraabdominal disease in the remaining three patients (acute diverticulitis: n = 1; appendicitis: n = 1; Crohn disease: n = 1) (25%). The mean duration of drainage was 9.5 days (range 3–33). Escherichia coli was the most frequently present microorganism (in 50.0% of the all samples). No procedure-related complications were observed, either during or after the procedure. Drainage was successful in 10 patients (83.3%). Drainage failed in one patient because of massive anastomotic dehiscence. The other one died from pulmonary embolus 10 days after drainage. Conclusions When an anterior or lateral transabdominal approach is inaccessible, CT-guided transperineal presacral space approach drainage is a safe, well-tolerated, and effective procedure, except for patients with massive anastomotic dehiscence.
- Published
- 2016
47. Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma
- Author
-
Yao Guo, Tao Yin, Heshui Wu, Chunyou Wang, Junling Zhu, Qi Qin, and Ming Yang
- Subjects
0301 basic medicine ,endocrine system diseases ,medicine.diagnostic_test ,biology ,Physiology ,Cell growth ,Chemistry ,Clinical Biochemistry ,Integrin ,RNA ,Cell Biology ,In situ hybridization ,Cell cycle ,digestive system diseases ,Flow cytometry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Downregulation and upregulation ,030220 oncology & carcinogenesis ,Cancer research ,medicine ,biology.protein ,Immunohistochemistry - Abstract
Long noncoding RNA (lncRNA) has been considered as potentially critical regulators in pancreatic ductal adenocarcinoma (PDAC). In this study, we prospectively investigate the effect and mechanism of lncRNA integrin subunit beta 2-anti-sense RNA 1 (ITGB2-AS1) on regulation of PDAC progression. The expression of ITGB2-AS1 and its target were analyzed by quantitative real-time polymerase chain reaction and in situ hybridization. 3-(4,5-Dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, wound healing, and transwell assays were used to investigate the influence of ITGB2-AS1 on cell proliferation, cell cycle, migration, and invasion, respectively. The interaction between ITGB2-AS1 and its target was determined via luciferase activity assay and RNA immunoprecipitation. The subcutaneous xenotransplanted tumor model was established and employed to detect the tumorigenic function of ITGB2-AS1, which was evaluated by western blot analysis, immunohistochemistry, and hematoxylin and eosin staining. The results showed that ITGB2-AS1 was elevated in both PDAC tumor tissues and cell lines, predicting a poor prognosis in PDAC patients. Knocking down of ITGB2-AS1 suppressed PDAC cell proliferation, invasion, and migration but induced cell apoptosis in vitro. Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1. ITGB2-AS1 promoted PDAC progression via inhibition of miR-4319. Interference of ITGB2-AS1 could suppress in vivo tumorigenic ability of PDAC via downregulation of RAF1. In conclusion, ITGB2-AS1 promoted PDAC progression via sponging miR-4319 to upregulate RAF1, suggesting the potential therapeutic target ability of ITGB2-AS1 in PDAC.
- Published
- 2019
48. Natural history and therapeutic strategies of post-pancreatoduodenectomy abdominal fluid collections: Ten-year experience in a single institution
- Author
-
Tao Peng, Ning Zhao, Jiong-xin Xiong, He-shui Wu, Jing Cui, Zhiyong Yang, and Chunyou Wang
- Subjects
Male ,Blood Loss, Surgical ,0302 clinical medicine ,Postoperative Complications ,Clinical Protocols ,Risk Factors ,Abdomen ,Retrospective analysis ,abdominal fluid collections ,030212 general & internal medicine ,Postoperative Period ,Single institution ,Aged, 80 and over ,Incidence (epidemiology) ,Incidence ,General Medicine ,Clinical Trial/Experimental Study ,respiratory system ,Middle Aged ,Natural history ,Treatment Outcome ,030220 oncology & carcinogenesis ,Drainage ,Female ,Research Article ,Adult ,medicine.medical_specialty ,management strategy ,Adolescent ,MEDLINE ,Pancreaticoduodenectomy ,03 medical and health sciences ,Pancreatic Fistula ,Young Adult ,Blood loss ,medicine ,Humans ,Pancreas ,Aged ,Retrospective Studies ,pancreatoduodenectomy ,Abdominal Fluid ,business.industry ,General surgery ,fungi ,Pancreatic Ducts ,Retrospective cohort study ,Logistic Models ,Multivariate Analysis ,business - Abstract
Trial Design: The aim of this study was to identify independent risk factors for post-pancreatoduodenectomy (post-PD) abdominal fluid collections (AFCs) and evaluate our management protocol on it. Methods: A retrospective analysis of consecutive 2064 cases who underwent PD over the past decade in 1 single center was conducted. The patients were divided into AFCs and non-AFCs group. Univariable and multivariate logistic regression analysis was performed to identify independent risk factors of AFCs. The AFCs group was compared with the non-AFCs group with respect to the incidence of postoperative outcomes. The characteristics of AFCs were further analyzed in terms of clinical manifestations. Results: Two thousand sixty-four cases with pancreaticoduodenectomy were recruited and 15% of them were found AFCs. Diameter of main pancreatic duct ≤3 mm was found to be an independent predictor of AFCs (P 800 mL (P
- Published
- 2019
49. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway
- Author
-
Shihong Wu, Chenggang Gao, Heshui Wu, Hehe Li, Chunyou Wang, Tao Yin, Qiang Shen, Qingke Duan, and Hengqiang Zhao
- Subjects
Blood Glucose ,Cytotoxicity, Immunologic ,Male ,0301 basic medicine ,Cancer Research ,Cell ,Gene Expression ,NK cells ,AMP-Activated Protein Kinases ,lcsh:RC254-282 ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Cell Line, Tumor ,Pancreatic cancer ,MICA/B ,Tumor Microenvironment ,medicine ,Animals ,Humans ,Cytotoxicity ,Polycomb Repressive Complex 1 ,Tumor microenvironment ,Chemistry ,Research ,Cell Membrane ,Histocompatibility Antigens Class I ,GATA2 ,AMPK ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,GATA2 Transcription Factor ,Killer Cells, Natural ,Pancreatic Neoplasms ,Immune surveillance ,Glucose ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,BMI1 ,030220 oncology & carcinogenesis ,Cancer research ,Tumor Escape ,High glucose ,Signal Transduction - Abstract
Background Modulation of cell surface expression of MHC class I chain-related protein A/B (MICA/B) has been proven to be one of the mechanisms by which tumor cells escape from NK cell-mediated killing. Abnormal metabolic condition, such as high glucose, may create a cellular stress milieu to induce immune dysfunction. Hyperglycemia is frequently presented in the majority of pancreatic cancer patients and is associated with poor prognosis. In this study, we aimed to detect the effects of high glucose on NK cell-mediated killing on pancreatic cancer cells through reduction of MICA/B expression. Methods The lysis of NK cells on pancreatic cancer cells were compared at different glucose concentrations through lactate dehydrogenase release assay. Then, qPCR, Western Blot, Flow cytometry and Immunofluorescence were used to identify the effect of high glucose on expression of MICA/B, Bmi1, GATA2, phosphorylated AMPK to explore the underlying mechanisms in the process. Moreover, an animal model with diabetes mellitus was established to explore the role of high glucose on NK cell-mediated cytotoxicity on pancreatic cancer in vivo. Results In our study, high glucose protects pancreatic cancer from NK cell-mediated killing through suppressing MICA/B expression. Bmi1, a polycomb group (PcG) protein, was found to be up-regulated by high glucose, and mediated the inhibition of MICA/B expression through promoting GATA2 in pancreatic cancer. Moreover, high glucose inhibited AMP-activated protein kinase signaling, leading to high expression of Bmi1. Conclusion Our findings identify that high glucose may promote the immune escape of pancreatic cancer cells under hyperglycemic tumor microenvironment. In this process, constitutive activation of AMPK-Bmi1-GATA2 axis could mediate MICA/B inhibition, which may serve as a therapeutic target for further intervention of pancreatic cancer immune evasion. Electronic supplementary material The online version of this article (10.1186/s13046-019-1209-9) contains supplementary material, which is available to authorized users.
- Published
- 2019
50. Cutaneous adverse drug reactions in Southwest China: Retrospective analysis of 448 cases of inpatients in a dermatology ward from 2010 to 2017
- Author
-
Xingwang Zhao, Zhiqiang Song, Chunyou Wang, Yi You, Lan Ge, and Ping Wang
- Subjects
Adult ,Male ,China ,Inpatients ,medicine.medical_specialty ,Adolescent ,business.industry ,Dermatology ,Middle Aged ,Risk Assessment ,Cohort Studies ,Young Adult ,Pharmaceutical Preparations ,Prevalence ,medicine ,Retrospective analysis ,Humans ,Female ,Drug Eruptions ,Drug reaction ,business ,Hospital Units ,Retrospective Studies - Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.